ESCRS 2026: Stellest 2.0 spectacle lens shows faster myopia control in early trial results

Mark Bullimore, PhD, MCOptom, of the University of Houston, presented early data from randomised clinical trials of the Stellest 2.0 spectacle lens (Essilor) during WSPOS Subspecialty Day, held in conjunction with the 44th Congress of the ESCRS in London. The session, aimed at the paediatric ophthalmology community, covered the latest results for the Stellest lens platform, which uses highly aspherical lenslet technology to slow myopic progression in children.

Conference context

Bullimore said the timing of the Stellest 2.0 data is notable: it comes, coincidentally, around the one-year anniversary of the original Stellest lens's authorisation by the FDA in the US, where it remains the only authorised myopia control spectacle lens. The original lens is also available in several other markets, including China, Malaysia, France, the UK, and Canada, and Stellest 2.0 has already reached those same markets while the second-generation trials continue.

Early trial results

According to Bullimore, the second-generation lens expands the power of its lenslets compared with the original design. In early results, slowing of myopic progression that previously took 12 months to achieve with the original lens was instead observed within six months, suggesting Stellest 2.0 may be roughly twice as effective. He described the shift to a second-generation design as delivering broadly improved efficacy, though he did not cite specific statistical detail during the session. He added that, certainly over the first six months, the new lens has shown the ability to stop myopia progression in its tracks, with minimal axial elongation observed over that period.

What's next

Bullimore said the one-year and two-year trial data, once available, are expected to be even more informative in demonstrating how effectively the lens slows myopic progression in children, with the goal of ultimately lowering the risk of disease and long-term visual impairment later in life.